Tredje AP fonden Has $6.50 Million Holdings in Regeneron Pharmaceuticals Inc (REGN)

Share on StockTwits

Tredje AP fonden grew its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 7.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,834 shares of the biopharmaceutical company’s stock after buying an additional 1,065 shares during the quarter. Tredje AP fonden’s holdings in Regeneron Pharmaceuticals were worth $6,502,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in REGN. Whittier Trust Co. increased its holdings in shares of Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 45 shares in the last quarter. Smithfield Trust Co. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. AdvisorNet Financial Inc increased its holdings in shares of Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 52 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $29,000. Finally, Captrust Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $30,000. Institutional investors own 66.97% of the company’s stock.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total transaction of $305,930.00. Following the sale, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The disclosure for this sale can be found here. Insiders have sold a total of 141,968 shares of company stock valued at $57,360,056 over the last 90 days. 11.84% of the stock is currently owned by insiders.

A number of equities analysts have recently issued reports on REGN shares. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Cantor Fitzgerald reiterated a “hold” rating and issued a $441.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. Oppenheimer increased their price target on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a report on Thursday, February 7th. Piper Jaffray Companies increased their price target on shares of Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Finally, Jefferies Financial Group cut their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $397.44.

NASDAQ:REGN traded down $3.11 during mid-day trading on Thursday, hitting $304.67. 8,440 shares of the company’s stock traded hands, compared to its average volume of 906,423. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals Inc has a 1 year low of $291.69 and a 1 year high of $442.00. The company has a market capitalization of $33.65 billion, a P/E ratio of 15.35, a price-to-earnings-growth ratio of 1.45 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same quarter last year, the business posted $4.67 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/4356966/tredje-ap-fonden-has-6-50-million-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: What is Put Option Volume?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Limestone Bancorp  vs. Centerstate Bank  Head to Head Analysis
Limestone Bancorp vs. Centerstate Bank Head to Head Analysis
Beasley Broadcast Group  & Spotify Technology  Head to Head Contrast
Beasley Broadcast Group & Spotify Technology Head to Head Contrast
Contrasting MacroGenics  & Prana Biotechnology
Contrasting MacroGenics & Prana Biotechnology
Contrasting Nexstar Media Group  & FOX
Contrasting Nexstar Media Group & FOX
Contrasting Superior Industries International  and Adomani
Contrasting Superior Industries International and Adomani
Renasant  & Sierra Bancorp  Head-To-Head Review
Renasant & Sierra Bancorp Head-To-Head Review


© 2006-2019 Ticker Report